文献速递支持与姑息治疗

免疫治疗疗效与毒性:审视患者可实施策略背后的证据

Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies.
PubMed 文献 · Eur J Cancer · 2024-07-22

本综述汇总肠道微生物组对免疫相关不良事件(irAE)发生影响的现有证据,并聚焦饮食调整、补充剂、药物管理和体力活动等可操作策略,以减轻irAE。随着免疫检查点抑制剂(ICI)适应证扩大,包括早期患者在内的相当比例肿瘤患者暴露于这些治疗,本综述为应对不断演变的免疫治疗挑战提供及时见解。

要点

  • 肠道微生物组与irAE发生相关性的证据尚不完整
  • 生活方式调整是改善治疗结局的有前景途径
  • 综述聚焦饮食、补充剂、药物管理和体力活动等可操作策略

核心结论

  • 本综述汇总肠道微生物组对irAE发生影响的现有证据,并聚焦饮食调整、补充剂、药物管理和体力活动等可操作策略以减轻irAE。

研究设计与样本

  • 综述类文章,检索范围未在原文中明确报告。

主要发现

  • ICI疗效数据分析增进了对应答者特征的理解,对发生irAE患者特征的认识也日益清晰,促使越来越重视与irAE风险相关的可改变因素,包括生活方式选择和肠道微生物组组成。
  • 尽管已有综述探讨微生物组在治疗疗效中的作用,但其与免疫相关毒性的联系仍不完整。
  • 识别预测性生物标志物的努力仍在继续,生活方式调整成为改善治疗结局的有前景途径。

局限性

  • 原文指出,尽管已有综述探讨微生物组在治疗疗效中的作用,但对其与免疫相关毒性的联系的理解仍不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of immune checkpoint inhibitors (ICI) in cancer treatment is expanding, offering promising outcomes but with an important risk of immune-related adverse events (irAEs). These events, stemming from an overstimulated immune system attacking healthy cells, can necessitate immunosuppressant treatment, disrupt treatment courses, and impact patients' quality of life. The analysis of ICI efficacy data has led to a better understanding of the characteristics of responders. Similarly, we are gaining clearer insights into the characteristics of patients who develop irAEs, prompting an increasing emphasis on modifiable factors associated with irAE risk. These factors include lifestyle choices and the composition of the gut microbiome. Despite comprehensive reviews exploring the microbiome's role in therapy efficacy, understanding its connection with immune-related toxicity remains incomplete. While endeavours to identify predictive biomarkers continue, lifestyle modifications emerge as a promising avenue for enhancing treatment outcomes. This review consolidates the current evidence regarding the impact of the gut microbiome on irAE occurrence. Furthermore, it focuses on actionable strategies for mitigating these adverse events, elucidating the evidence supporting dietary adjustments, supplementation, medication management, and physical activity. With the expanding range of indications for ICI therapy, a significant proportion of oncology patients, including those in early disease stages, are now exposed to these treatments. Acknowledging the importance of averting irAEs in this context, our review offers timely insights crucial for addressing the evolving challenges associated with immunotherapy across diverse oncological settings.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Verhaert MAM, Aspeslagh S. Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies. Eur J Cancer. 2024. PMID: 39059186. doi:10.1016/j.ejca.2024.114235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。